title: Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer.
abstract: Sipuleucel-T is a therapeutic cancer vaccine that has shown improved survival in men with metastatic castration-resistant prostate cancer. As a first-in-class agent, it has been met with both fan-fare and controversy. A broad review of immune-based therapies may reveal the delayed clinical impact of sipuleucel-T to be a class effect. As new strategies of immune-based therapy are developed, their effects can be optimized through better understanding of how they affect disease differently from more standard therapeutics. Furthermore, combination therapy with agents that can either work synergistically with immune-activating therapies or deplete immune-regulating cells may result in more vigorous immune responses and improved clinical outcomes. In addition, therapeutic vaccines may be ideal candidates to safely combine with standard-of-care therapies because of their nonoverlapping toxicity profile. The ultimate role of immunotherapy may not be to supplant standard therapies, but rather to work in concert with them to maximize clinical benefit for patients.
authors.affiliation: National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Ravi A
authors.initials: RA
authors.lastname: Madan
authors.forename: Thomas
authors.initials: T
authors.lastname: Schwaab
authors.forename: James L
authors.initials: JL
authors.lastname: Gulley
mesh_terms: D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology; D006801:Humans; D007113:Immunity, Innate; D007167:Immunotherapy; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D014020:Tissue Extracts / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D019496:Cancer Vaccines; D014020:Tissue Extracts; C511774:sipuleucel-T